Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2025-04-15 Sale |
2025-04-16 6:00 pm |
Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer |
9,073 | $37.91 | $343,962 | 115,034 (Direct) |
View |
| 2025-04-10 Sale |
2025-04-11 6:00 pm |
Akero Therapeutics Inc. | AKRO | Cheng Andrew President and CEO |
30,000 | $35.23 | $1,056,780 | 624,324 (Direct) |
View |
| 2025-04-07 Sale |
2025-04-10 6:00 pm |
Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer |
6,250 | $35.88 | $224,262 | 198,439 (Direct) |
View |
| 2025-03-25 Purchase |
2025-03-27 7:42 pm |
Akero Therapeutics Inc. | AKRO | Graham G. Walmsley Director |
200,000 | $43.94 | $8,787,921 | 1,202,168 (Indirect Direct) |
View |
| 2025-03-17 Sale |
2025-03-18 5:30 pm |
Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer |
10,000 | $44.76 | $447,605 | 95,034 (Direct) |
View |
| 2025-03-12 Sale |
2025-03-14 9:18 pm |
Akero Therapeutics Inc. | AKRO | Cheng Andrew President and CEO |
1,738 | $44.88 | $78,001 | 654,324 (Direct) |
View |
| 2025-03-12 Sale |
2025-03-14 8:33 pm |
Akero Therapeutics Inc. | AKRO | Young Jonathan Chief Operating Officer |
607 | $44.88 | $27,242 | 260,540 (Indirect Direct) |
View |
| 2025-03-12 Sale |
2025-03-14 8:30 pm |
Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer |
614 | $44.88 | $27,556 | 95,034 (Direct) |
View |
| 2025-03-12 Sale |
2025-03-14 8:24 pm |
Akero Therapeutics Inc. | AKRO | White William Richard Chief Financial Officer |
676 | $44.88 | $30,339 | 61,959 (Direct) |
View |
| 2025-03-12 Sale |
2025-03-14 8:18 pm |
Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer |
516 | $44.88 | $23,158 | 169,721 (Direct) |
View |
| 2025-03-10 Sale |
2025-03-12 6:00 pm |
Akero Therapeutics Inc. | AKRO | Cheng Andrew President and CEO |
30,000 | $41.77 | $1,253,069 | 656,062 (Direct) |
View |
| 2025-03-05 Sale |
2025-03-07 5:30 pm |
Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer |
12,500 | $44.53 | $556,590 | 205,205 (Direct) |
View |
| 2025-03-04 Sale |
2025-03-05 6:56 pm |
Akero Therapeutics Inc. | AKRO | Young Jonathan Chief Operating Officer |
50,000 | $44.86 | $2,243,213 | 261,147 (Indirect Direct) |
View |
| 2025-03-03 Sale |
2025-03-05 6:55 pm |
Akero Therapeutics Inc. | AKRO | Lamy Patrick Senior VP, Commercial Strategy |
1,000 | $48.09 | $48,090 | 111,674 (Direct) |
View |
| 2025-02-18 Sale |
2025-02-21 5:31 pm |
Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer |
10,000 | $49.87 | $498,660 | 105,648 (Direct) |
View |
| 2025-02-10 Sale |
2025-02-11 9:30 pm |
Akero Therapeutics Inc. | AKRO | Cheng Andrew President and CEO |
30,000 | $52.73 | $1,581,994 | 686,062 (Direct) |
View |
| 2025-01-30 Purchase |
2025-02-07 7:54 pm |
Akero Therapeutics Inc. | AKRO | Graham G. Walmsley Director |
200,000 | $48 | $9,600,000 | 1,002,168 (Indirect Direct) |
View |
| 2025-02-05 Sale |
2025-02-07 6:05 pm |
Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer |
18,750 | $56.51 | $1,059,630 | 217,705 (Direct) |
View |
| 2025-02-03 Sale |
2025-02-05 09:03 am |
Akero Therapeutics Inc. | AKRO | Young Jonathan Chief Operating Officer |
10,000 | $53.81 | $538,061 | 311,147 (Indirect Direct) |
View |
| 2025-01-27 Sale |
2025-01-31 09:14 am |
Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer |
53,590 | $56.25 | $3,014,216 | 148,433 (Direct) |
View |
| 2025-01-27 Sale |
2025-01-31 09:14 am |
Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer |
49,074 | $55.72 | $2,734,212 | 149,069 (Direct) |
View |
| 2025-01-27 Sale |
2025-01-29 8:43 pm |
Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer |
31,250 | $55.77 | $1,742,958 | 356,424 (Direct) |
View |
| 2025-01-27 Sale |
2025-01-29 8:43 pm |
Akero Therapeutics Inc. | AKRO | Lamy Patrick Senior VP, Commercial Strategy |
5,000 | $57.03 | $285,150 | 112,674 (Direct) |
View |
| 2025-01-27 Sale |
2025-01-29 8:43 pm |
Akero Therapeutics Inc. | AKRO | Cheng Andrew President and CEO |
30,000 | $54.9 | $1,646,978 | 716,062 (Direct) |
View |
| 2025-01-02 Sale |
2025-01-06 2:08 pm |
Akero Therapeutics Inc. | AKRO | Young Jonathan Chief Operating Officer |
10,000 | $28.03 | $280,330 | 278,083 (Indirect Direct) |
View |
| 2024-12-16 Sale |
2024-12-18 9:03 pm |
Akero Therapeutics Inc. | AKRO | Lamy Patrick Senior VP, Commercial Strategy |
1,000 | $29.13 | $29,130 | 86,358 (Direct) |
View |
| 2024-12-16 Sale |
2024-12-18 9:01 pm |
Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer |
9,074 | $29.11 | $264,117 | 189,348 (Direct) |
View |
| 2024-12-17 Sale |
2024-12-18 8:52 pm |
Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer |
3,800 | $31.1 | $118,172 | 393,292 (Direct) |
View |
| 2024-12-10 Sale |
2024-12-12 8:44 pm |
Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer |
4,818 | $30.91 | $148,934 | 317,092 (Direct) |
View |
| 2024-12-10 Sale |
2024-12-12 8:38 pm |
Akero Therapeutics Inc. | AKRO | Young Jonathan Chief Operating Officer |
2,503 | $30.79 | $77,067 | 263,783 (Indirect Direct) |
View |
| 2024-12-10 Sale |
2024-12-12 8:29 pm |
Akero Therapeutics Inc. | AKRO | Lamy Patrick Senior VP, Commercial Strategy |
925 | $30.79 | $28,481 | 17,858 (Direct) |
View |
| 2024-12-10 Sale |
2024-12-12 8:28 pm |
Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer |
2,810 | $30.79 | $86,520 | 71,348 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-04-15 Exercise |
2025-04-16 6:00 pm |
N/A 2031-12-07 |
Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer |
9,073 | $0 | 115,034 (Direct) |
View |
| 2025-04-15 Exercise |
2025-04-16 6:00 pm |
N/A N/A |
Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer |
9,073 | $21.1 | 115,034 (Direct) |
View |
| 2025-04-07 Exercise |
2025-04-10 6:00 pm |
N/A 2031-12-07 |
Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer |
6,250 | $0 | 198,439 (Direct) |
View |
| 2025-04-07 Exercise |
2025-04-10 6:00 pm |
N/A N/A |
Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer |
6,250 | $21.1 | 198,439 (Direct) |
View |
| 2025-03-17 Exercise |
2025-03-18 5:30 pm |
N/A 2031-12-07 |
Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer |
10,000 | $0 | 95,034 (Direct) |
View |
| 2025-03-17 Exercise |
2025-03-18 5:30 pm |
N/A N/A |
Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer |
10,000 | $21.1 | 95,034 (Direct) |
View |
| 2025-03-05 Exercise |
2025-03-07 5:30 pm |
N/A 2031-12-07 |
Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer |
12,500 | $0 | 205,205 (Direct) |
View |
| 2025-03-05 Exercise |
2025-03-07 5:30 pm |
N/A N/A |
Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer |
12,500 | $21.1 | 205,205 (Direct) |
View |
| 2025-03-03 Exercise |
2025-03-05 6:55 pm |
N/A 2033-12-07 |
Akero Therapeutics Inc. | AKRO | Lamy Patrick Senior VP, Commercial Strategy |
1,000 | $0 | 111,674 (Direct) |
View |
| 2025-03-03 Exercise |
2025-03-05 6:55 pm |
N/A N/A |
Akero Therapeutics Inc. | AKRO | Lamy Patrick Senior VP, Commercial Strategy |
1,000 | $19.87 | 111,674 (Direct) |
View |
| 2025-02-18 Exercise |
2025-02-21 5:31 pm |
N/A 2031-12-07 |
Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer |
10,000 | $0 | 105,648 (Direct) |
View |
| 2025-02-18 Exercise |
2025-02-21 5:31 pm |
N/A N/A |
Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer |
10,000 | $21.1 | 105,648 (Direct) |
View |
| 2025-02-05 Exercise |
2025-02-07 6:05 pm |
N/A 2031-12-07 |
Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer |
18,750 | $0 | 217,705 (Direct) |
View |
| 2025-02-05 Exercise |
2025-02-07 6:05 pm |
N/A N/A |
Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer |
18,750 | $21.1 | 217,705 (Direct) |
View |
| 2025-01-27 Exercise |
2025-01-31 09:14 am |
N/A 2028-10-17 |
Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer |
53,590 | $0 | 148,433 (Direct) |
View |
| 2025-01-27 Exercise |
2025-01-31 09:14 am |
N/A N/A |
Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer |
15,172 | $6.364 | 148,433 (Direct) |
View |
| 2025-01-27 Exercise |
2025-01-31 09:14 am |
N/A N/A |
Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer |
21,569 | $21.09 | 148,433 (Direct) |
View |
| 2025-01-27 Exercise |
2025-01-31 09:14 am |
N/A N/A |
Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer |
16,849 | $0.615 | 148,433 (Direct) |
View |
| 2025-01-27 Exercise |
2025-01-31 09:14 am |
N/A 2031-12-07 |
Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer |
49,074 | $0 | 149,069 (Direct) |
View |
| 2025-01-27 Exercise |
2025-01-31 09:14 am |
N/A N/A |
Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer |
49,074 | $21.1 | 149,069 (Direct) |
View |
| 2025-01-27 Exercise |
2025-01-29 8:43 pm |
N/A 2033-12-08 |
Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer |
31,250 | $0 | 356,424 (Direct) |
View |
| 2025-01-27 Exercise |
2025-01-29 8:43 pm |
N/A N/A |
Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer |
14,986 | $19.87 | 356,424 (Direct) |
View |
| 2025-01-27 Exercise |
2025-01-29 8:43 pm |
N/A N/A |
Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer |
16,264 | $21.1 | 356,424 (Direct) |
View |
| 2024-12-31 Option Award |
2025-01-29 8:43 pm |
N/A N/A |
Akero Therapeutics Inc. | AKRO | Lamy Patrick Senior VP, Commercial Strategy |
234 | $19.69 | 112,674 (Direct) |
View |
| 2025-01-27 Exercise |
2025-01-29 8:43 pm |
N/A 2033-12-07 |
Akero Therapeutics Inc. | AKRO | Lamy Patrick Senior VP, Commercial Strategy |
4,000 | $0 | 112,674 (Direct) |
View |
| 2025-01-27 Exercise |
2025-01-29 8:43 pm |
N/A N/A |
Akero Therapeutics Inc. | AKRO | Lamy Patrick Senior VP, Commercial Strategy |
4,000 | $19.87 | 112,674 (Direct) |
View |
| 2025-01-23 Exercise |
2025-01-27 6:08 pm |
N/A 2029-01-15 |
Akero Therapeutics Inc. | AKRO | Young Jonathan Chief Operating Officer |
43,064 | $0 | 321,147 (Direct) |
View |
| 2025-01-24 Exercise |
2025-01-27 6:08 pm |
N/A N/A |
Akero Therapeutics Inc. | AKRO | Young Jonathan Chief Operating Officer |
43,064 | $6.364 | 321,147 (Direct) |
View |
| 2025-01-23 Exercise |
2025-01-27 6:07 pm |
N/A 2028-09-07 |
Akero Therapeutics Inc. | AKRO | Cheng Andrew President and CEO |
50,000 | $0 | 798,274 (Direct) |
View |
| 2025-01-23 Exercise |
2025-01-27 6:07 pm |
N/A N/A |
Akero Therapeutics Inc. | AKRO | Cheng Andrew President and CEO |
50,000 | $0.615 | 798,274 (Direct) |
View |
| 2025-01-07 Gift |
2025-01-10 7:38 pm |
N/A N/A |
Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer |
14,000 | $0 | 170,237 (Direct) |
View |
| 2024-12-26 Gift |
2024-12-30 8:20 pm |
N/A N/A |
Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer |
14,100 | $0 | 184,237 (Direct) |
View |
| 2024-12-16 Option Award |
2024-12-18 9:08 pm |
N/A 2034-12-15 |
Akero Therapeutics Inc. | AKRO | Young Jonathan Chief Operating Officer |
98,000 | $0 | 361,783 (Direct) |
View |
| 2024-12-16 Option Award |
2024-12-18 9:03 pm |
N/A 2034-12-15 |
Akero Therapeutics Inc. | AKRO | Lamy Patrick Senior VP, Commercial Strategy |
69,500 | $0 | 86,358 (Direct) |
View |
| 2024-12-16 Exercise |
2024-12-18 9:01 pm |
N/A 2031-12-07 |
Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer |
9,074 | $0 | 189,348 (Direct) |
View |
| 2024-12-16 Option Award |
2024-12-18 9:01 pm |
N/A 2034-12-15 |
Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer |
98,000 | $0 | 189,348 (Direct) |
View |
| 2024-12-16 Exercise |
2024-12-18 9:01 pm |
N/A N/A |
Akero Therapeutics Inc. | AKRO | Yale Catriona Chief Development Officer |
9,074 | $21.1 | 189,348 (Direct) |
View |
| 2024-12-16 Option Award |
2024-12-18 8:59 pm |
N/A 2034-12-15 |
Akero Therapeutics Inc. | AKRO | White William Richard Chief Financial Officer |
98,000 | $0 | 136,335 (Direct) |
View |
| 2024-12-16 Option Award |
2024-12-18 8:56 pm |
N/A 2034-12-15 |
Akero Therapeutics Inc. | AKRO | Gangloff Scott A. Chief Technology Officer |
98,000 | $0 | 98,000 (Direct) |
View |
| 2024-12-17 Exercise |
2024-12-18 8:52 pm |
N/A 2033-12-08 |
Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer |
3,800 | $0 | 393,292 (Direct) |
View |
| 2024-12-17 Exercise |
2024-12-18 8:52 pm |
N/A N/A |
Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer |
3,800 | $19.87 | 393,292 (Direct) |
View |
| 2024-12-16 Option Award |
2024-12-18 8:52 pm |
N/A 2034-12-15 |
Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer |
80,000 | $0 | 393,292 (Direct) |
View |
| 2024-12-16 Option Award |
2024-12-18 8:50 pm |
N/A 2034-12-15 |
Akero Therapeutics Inc. | AKRO | Cheng Andrew President and CEO |
394,100 | $0 | 991,662 (Direct) |
View |
| 2024-12-10 Exercise |
2024-12-12 8:44 pm |
N/A 2033-12-08 |
Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer |
2,450 | $0 | 317,092 (Direct) |
View |
| 2024-12-10 Exercise |
2024-12-12 8:44 pm |
N/A N/A |
Akero Therapeutics Inc. | AKRO | Rolph Timothy Chief Scientific Officer |
2,450 | $19.87 | 317,092 (Direct) |
View |